Press Releases

NEW YORK, April 27, 2026 /PRNewswire/ -- LifeStance Health Group Inc. (NASD: LFST) will replace Golden Entertainment Inc (NASD: GDEN) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, May 1. S&P 500 constituent VICI Properties Inc. (NYSE:VICI) and Blake Sartini are acquiring Golden Entertainment in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name ActionCompany NameTickerGICS SectorMay 1, 2026S&P SmallCap 600AdditionLifeStance Health GroupLFSTHealth CareMay 1, 2026S&P SmallCap 600DeletionGolden EntertainmentGDENConsum

CBRE Group, Inc. (NYSE:CBRE) (the "Company") today announced the pricing of the offering of $750,000,000 aggregate principal amount of 5.250% Senior Notes due 2036 (the "Notes"). The Notes will have an interest rate of 5.250% per annum and are being issued at a price equal to 98.947% of their face value. The Company's wholly owned subsidiary, CBRE Services, Inc. ("Services"), will issue the Notes, which will be guaranteed on a full and unconditional basis by the Company. The Notes are expected to settle on May 4, 2026, subject to the satisfaction of customary closing conditions. The Company estimates that the net proceeds from the offering will be approximately $737 million, after deducti

ATHENS, Greece, April 27, 2026 (GLOBE NEWSWIRE) -- Global Ship Lease, Inc. (NYSE:GSL) (the "Company") has scheduled its Annual Meeting of Shareholders for June 17, 2026, at 10:00 a.m. Eastern Time (the "Annual Meeting"). The record date for determining shareholders entitled to participate at the Annual Meeting is April 20, 2026. The business of the Annual Meeting is to (i) elect three Term III Directors to serve until the 2029 Annual Meeting of Shareholders, (ii) ratify the appointment of PricewaterhouseCoopers S.A., as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, and (iii) to approve the Company's Second Amended and Restated Art

PANAMA CITY, April 27, 2026 /PRNewswire/ -- Bladex (NYSE:BLX, or ", the Bank", )), a Panama-based multinational bank originally established by the central banks of 23 Latin-American and Caribbean countries to promote foreign trade and economic integration in the Region, announced today its results for the First Quarter ("1Q26") ended March 31, 2026. The consolidated financial information in this document has been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").  Financial & Business HighlightsSolid profitability with Net Profits reaching $56.4 million in 1Q26 (+9% YoY), supported by continued

PANAMA CITY, April 27, 2026 /PRNewswire/ -- Bladex announced today its Board of Directors' approval of a quarterly cash dividend of US$0.6875 per share corresponding to the first quarter of 2026. The cash dividend is payable May 27, 2026 to the Bank's stockholders as of May 8, 2026 record date.As of March 31, 2026, Bladex had 37,536,498.88 shares outstanding of all classes.Bladex, a multinational bank originally established by the central banks of Latin-American and Caribbean countries, began operations in 1979 to promote foreign trade and economic integration in the Region.  The Bank, headquartered in Panama, also has offices in Argentina, Brazil, Colombia, Mexico, the United States of Amer

MINNEAPOLIS, April 28, 2026 /PRNewswire/ -- Polaris Inc. (NYSE:PII) reported first quarter 2026 financial results today through an earnings release posted on the Company's Investor Relations website at ir.polaris.com.  The earnings release will be furnished with the Securities and Exchange Commission on a Form 8-K and is available at sec.gov.  The Company will also hold a conference call with analysts and investors today at 9:00 a.m. CT. Conference Call and Webcast DetailsThe call and webcast can be accessed via the Webcast link on our website at ir.polaris.com or by dialing 1-8

Revenues of $2.05 billionNet income of $19 million, or $0.05 per shareAdjusted EBITDA* of $177 millionBookings of $520 million, representing a book-to-bill of 80%Returned $100 million of capital to shareholders through share repurchases and dividends *Free Cash Flow, Excess Free Cash Flow, Adjusted Operating Profit, and Adjusted EBITDA are non-GAAP measures, see "Non-GAAP Financial Measures," and "Reconciliation of GAAP to non-GAAP measures" below. HOUSTON, April 27, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE:NOV) today reported first quarter 2026 revenues of $2.05 billion, a decrease of two percent compared to the first quarter of 2025. Net income decreased $54 million, or $0.14 per dilu

Turning Point Brands, Inc. (NYSE:TPB) announced the date and time for its conference call to review first quarter 2026 results. The conference call will be on Thursday, May 7, 2026 at 8:30 a.m. Eastern Time. Interested analysts and professional investors can register and participate through one of these call-in numbers: (800) 715-9871 (U.S., toll-free) (646) 307-1963 (International) Event ID: 4128483 Participants should dial in at least ten minutes in advance and follow the audio prompts after typing in the Event ID. The call will also be broadcast live as a listen-only webcast from the investor relations section of the company's website at http://www.turningpointbrands.com/investor-r

ATHENS, Greece, April 27, 2026 (GLOBE NEWSWIRE) -- Performance Shipping Inc. (NASDAQ:PSHG), ("we" or the "Company"), a global shipping company specializing in the ownership of tanker vessels, announced that it has filed its 2025 Annual Report on Form 20-F for the fiscal year ended December 31, 2025 (the "Annual Report"), with the U.S. Securities and Exchange Commission (the "SEC"). The Annual Report, which contains the Company's audited consolidated financial statements, can be accessed through the SEC's website at http://www.sec.gov as well as through the Company's website at http://www.pshipping.com. Upon request, we will provide any shareholder with a hard copy of the Annual Report free

A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence observed through Week 52, with mean C-peptide AUC largely preserved in 200 mg group (~7% decline from baseline) following only 12 weeks of dosingPreservation of C-peptide also observed in patients diagnosed between 3-15 years (n=9)Icovamenib was generally well tolerated across all dosing arms and demonstrated a favorable safety and tolerability profile through Week 52 Comprehensive dataset to be presented at the American Diabetes Association's (ADA) Scientific Sessions (abstract is preliminary un

Vancouver, British Columbia--(Newsfile Corp. - April 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into amending agreements in respect of preferred investment options previously entered into with each of Sabby Volatility Warrant Master Fund, Ltd. ("Sabby") and certain affiliates of H.C. Wainwright & Co., LLC (the "Wainwright Parties").As previously reported: pursuant to the terms of the preferred investment options dated October 26, 2023 and June 26, 2025 (together, the "Sabby

CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, May 11, 2026, at 8:30 a.m. ET to report first quarter 2026 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the

MILWAUKEE, April 27, 2026 /PRNewswire/ -- Louis Pinkham, Chief Executive Officer of Regal Rexnord Corporation (NYSE:RRX), announced that the Board of Directors, at its regular quarterly meeting held on April 27, 2026, declared a dividend of $0.35 per share. The dividend is payable on July 14, 2026, to shareholders of record at the close of business on June 30, 2026. The company has paid a dividend every quarter since January 1961. About Regal RexnordRegal Rexnord's 30,000 associates around the world help create a better tomorrow by providing sustainable solutions that power, transmit and control motion. The Company's electric motors and air moving subsystems provide the power to create motio

Veradermics, Incorporated ("Veradermics") (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that it has launched a proposed public offering of 3,350,000 shares of common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock) pursuant to a registration statement filed on Form S-1 with the Securities and Exchange Commission ("SEC"). All of the shares and pre-funded warrants are being offered by Veradermics. In addition, the underwriters are expected to have a 30-day option to purchase up to an additional 502,500 s

BBB Foods Inc. (NYSE:TBBB) ("Tiendas 3B" or "the Company") will report its first quarter 2026 earnings on May 6, 2026, after market close. You are invited to join our quarterly conference call, which will be webcast on May 7, 2026, at 12:00 p.m. ET. Anthony Hatoum, Chairman and CEO, and Eduardo Pizzuto, CFO, will host the call and take questions on the results. Event: Tiendas 3B First Quarter 2026 Earnings Conference Call When: May 7, 2026, 12:00 p.m. ET Webinar /Dial In #: To join the webinar: https://zoom.us/webinar/register/WN_gw598N0ZSMeMhTncXb-3LA To join via telephone: Dial one of the domestic or international numbers listed below. Enter the webinar ID (962 4278 7223)

In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS by lumbar IT administration MiniMeCP2 is functionally comparable to full-length MeCP2 across molecular and biochemical functions, with both proteins exhibiting comparable, stable expression in neuronal cells Data further validate the selection of scAAV9 and miniMeCP2 in the TSHA-102 construct and provide translational support for the Part A REVEAL Phase 1/2 clinical data in patients with Rett syndrome DALLAS, April 27, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its cardiac gene therapy programs and optimized AAV manufacturing approach will be presented at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 11-15, 2026 in Boston, MA. "We're excited to return to ASGCT with a broad and compelling set of presentations that highlight the depth of Lexeo's science and continued progress across our pipeline, from encouraging cardiac and neurologic data in Friedreich ataxia (FA

PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics' first regulatory approval outside of the U.S., with first launch planned for Germany and Austria SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that the European Commission (EC) has approved PALSONIFY® (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the treatment of adult patients with acromegaly

Features company's patented SimpliSqueeze® valve for ready-to-dispense convenience, focused on reducing mess and drips AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced it has launched a new line of inverted lidless dispensing closures for the beauty and personal care markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427887104/en/Aptar's Inverted Lidless Dispensing Closures Aptar's inverted lidless closures help eliminate the need for separate lids while allowing for an inverted, ready-to-dispense packaging format that he

DAYTONA BEACH, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE:BRO) (the "Company") announced its unaudited financial results for the first quarter of 2026. For the first quarter ended March 31, 2026, the Company achieved: Total revenues of $1.9 billion, increasing $497 million, or 35.4%, compared to the first quarter of the prior year, with flat Organic Revenue and Organic Revenue with Contingents increasing 2.2%.Income before income taxes of $533 million, increasing 24.8%, with Income Before Income Taxes Margin of 28.0%, compared to 30.4% in the first quarter of the prior year.EBITDAC - Adjusted of $731 million, increasing 36.6%, with EBITDAC Margin - Adjusted of 38.